Tag: Atypical reversible MAO-A inhibitor

  • Pirlindole

    Atypical reversible MAO-A inhibitor

    A pyrazinocarbazole RIMA developed in the USSR in the 1970s; the historical Soviet RIMA equivalent.

    Abstract

    Pirlindole (2,3,3a,4,5,6-hexahydro-8-methyl-1H-pyrazino[3,2,1-jk]carbazole; CAS 60762-57-4; molecular formula C15H18N2; molecular weight 226.32) is a pyrazinocarbazole RIMA developed at the Soviet Academy of Sciences in the 1970s and registered in the USSR in 1975 under the trade name Pyrazidol. The compound is a reversible competitive MAO-A inhibitor with secondary 5-HT2 antagonism contributing to its antidepressant profile. Clinical efficacy has been documented in Soviet and post-Soviet trials in major depressive disorder, dysthymia, and reactive depression; head-to-head data versus moclobemide are sparse. Plasma half-life is approximately 2 to 4 hours; metabolism is hepatic. The compound is well tolerated relative to hydrazine MAOIs and does not require tyramine restriction at clinical doses. Approval is restricted to Russia and former Soviet states; not registered in the US, EU, or other Western markets. Used as the historical reference RIMA from the Soviet pharmacological tradition.

    FOR RESEARCH USE ONLY. Not for medical, diagnostic, or therapeutic purposes. Not for human or animal consumption. All information is provided for research and educational purposes only.